Fc or not Fc; that is the question: Antibody Fc-receptor interactions are key to universal influenza vaccine design

Human Vaccines and Immunotherapeutics

Volumn 13, Issue 6, 2017, Pages 1288-1296

  Jegaskanda, Sinthujan ^a   Vanderven, Hillary A ^a   Wheatley, Adam K ^a   Kent, Stephen J ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

antibody dependent cellular cytotoxicity; influenza; monoclonal antibodies; universal vaccine

Indexed keywords

FC RECEPTOR; INFLUENZA VACCINE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VIRAL PROTEIN; VIRUS ANTIBODY;

ADAPTIVE IMMUNITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY TITER; CROSS REACTION; DNA FRAGMENTATION; DRUG ANTIGENICITY; DRUG DESIGN; DRUG RECEPTOR BINDING; EFFECTOR CELL; HUMAN; IMMUNE RESPONSE; INFLUENZA; INFLUENZA VIRUS; INNATE IMMUNITY; MOLECULAR INTERACTION; NONHUMAN; NOTE; PROTEIN CONFORMATION; VIRUS NEUTRALIZATION; DRUG DEVELOPMENT; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; ORTHOMYXOVIRIDAE; TRENDS;

ANTIBODIES, VIRAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; DRUG DISCOVERY; HUMANS; INFLUENZA VACCINES; ORTHOMYXOVIRIDAE; RECEPTORS, FC;

EID: 85017008619     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2017.1290018     Document Type: Note

References (88)

1. WHO. Influenza (Seasonal), Fact sheet. http://www.who.int/mediacentre/factsheets/fs211/en/, 2016
2. Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, Bridges CB. The annual impact of seasonal influenza in the US:measuring disease burden and costs. Vaccine 2007; 25:5086-96; PMID:17544181; https://doi.org/10.1016/j.vaccine.2007.03.046
3. Radin JM, Hawksworth AW, Myers CA, Ricketts MN, Hansen EA, Brice GT. Influenza vaccine effectiveness:Maintained protection throughout the duration of influenza seasons 2010-2011 through 2013-2014. Vaccine 2016; 34:3907-12; PMID:27265447; https://doi.org/10.1016/j.vaccine.2016.05.034
4. Bedford T, Suchard MA, Lemey P, Dudas G, Gregory V, Hay AJ, McCauley JW, Russell CA, Smith DJ, Rambaut A. Integrating influenza antigenic dynamics with molecular evolution. Elife 2014; 3:e01914; https://doi.org/10.7554/eLife.01914
5. Impagliazzo A, Milder F, Kuipers H, Wagner MV, Zhu X, Hoffman RM, van Meersbergen R, Huizingh J, Wanningen P, Verspuij J, et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science 2015; 349:1301-6; PMID:26303961; https://doi.org/10.1126/science.aac7263
6. Yassine HM, Boyington JC, McTamney PM, Wei CJ, Kanekiyo M, Kong WP, Gallagher JR, Wang L, Zhang Y, Joyce MG, et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat Med 2015; 21:1065-70; PMID:26301691; https://doi.org/10.1038/nm.3927
7. Mallajosyula VV, Citron M, Ferrara F, Lu X, Callahan C, Heidecker GJ, Sarma SP, Flynn JA, Temperton NJ, Liang X, et al. Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection. Proc Natl Acad Sci U S A 2014; 111:E2514-23; PMID:24927560; https://doi.org/10.1073/pnas.1402766111
8. Valkenburg SA, Mallajosyula VV, Li OT, Chin AW, Carnell G, Temperton N, Varadarajan R, Poon LL. Stalking influenza by vaccination with pre-fusion headless HA mini-stem. Sci Rep 2016; 6:22666; PMID:26947245; https://doi.org/10.1038/srep22666
9. Song JM, Van Rooijen N, Bozja J, Compans RW, Kang SM. Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus. Proc Natl Acad Sci U S A 2011; 108:757-61; PMID:21187388; https://doi.org/10.1073/pnas.1012199108
10. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 1999; 5:1157-63; PMID:10502819; https://doi.org/10.1038/13484
11. De Filette M, Martens W, Smet A, Schotsaert M, Birkett A, Londono-Arcila P, Fiers W, Saelens X. Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies. Vaccine 2008; 26:6503-7; PMID:18835315; https://doi.org/10.1016/j.vaccine.2008.09.038
12. De Filette M, Min Jou W, Birkett A, Lyons K, Schultz B, Tonkyro A, Resch S, Fiers W. Universal influenza A vaccine:optimization of M2-based constructs. Virology 2005; 337:149-61; PMID:15914228; https://doi.org/10.1016/j.virol.2005.04.004
13. Huleatt JW, Nakaar V, Desai P, Huang Y, Hewitt D, Jacobs A, Tang J, McDonald W, Song L, Evans RK, et al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 2008; 26:201-14; PMID:18063235; https://doi.org/10.1016/j.vaccine.2007.10.062
14. Kolpe A, Schepens B, Fiers W, Saelens X. M2-based influenza vaccines:recent advances and clinical potential. Expert Rev Vaccines 2016:16(2):123-136
15. Liu WC, Lin CY, Tsou YT, Jan JT, Wu SC. Cross-reactive neuraminidase-inhibiting antibodies elicited by immunization with recombinant neuraminidase proteins of H5N1 and pandemic H1N1 influenza a viruses. J Virol 2015; 89:7224-34; PMID:25948745; https://doi.org/10.1128/JVI.00585-15
16. Eichelberger MC, Wan H. Influenza neuraminidase as a vaccine antigen. Curr Top Microbiol Immunol 2015; 386:275-99; PMID:25033754
17. Sridhar S. Heterosubtypic T-Cell Immunity to Influenza in Humans:Challenges for Universal T-Cell Influenza Vaccines. Front Immunol 2016; 7:195; PMID:27242800; https://doi.org/10.3389/fimmu.2016.00195
18. He W, Mullarkey CE, Duty JA, Moran TM, Palese P, Miller MS. Broadly neutralizing anti-influenza virus antibodies:enhancement of neutralizing potency in polyclonal mixtures and IgA backbones. J Virol 2015; 89:3610-8; PMID:25589655; https://doi.org/10.1128/JVI.03099-14
19. He W, Mullarkey CE, Miller MS. Measuring the neutralization potency of influenza A virus hemagglutinin stalk/stem-binding antibodies in polyclonal preparations by microneutralization assay. Methods 2015; 90:95-100; PMID:25957674; https://doi.org/10.1016/j.ymeth.2015.04.037
20. O'Brien KB, Morrison TE, Dundore DY, Heise MT, Schultz-Cherry S. A protective role for complement C3 protein during pandemic 2009 H1N1 and H5N1 influenza A virus infection. PLoS One 2011; 6:e17377; https://doi.org/10.1371/journal.pone.0017377
21. Ohta R, Torii Y, Imai M, Kimura H, Okada N, Ito Y. Serum concentrations of complement anaphylatoxins and proinflammatory mediators in patients with 2009 H1N1 influenza. Microbiol Immunol 2011; 55:191-8; https://doi.org/10.1111/j.1348-0421.2011.00309.x
22. Terajima M, Co MD, Cruz J, Ennis FA. High Antibody-Dependent Cellular Cytotoxicity Antibody Titers to H5N1 and H7N9 Avian Influenza A Viruses in Healthy US Adults and Older Children. J Infect Dis 2015; 212:1052-60; PMID:25795791; https://doi.org/10.1093/infdis/jiv181
23. Quinnan GV, Ennis FA, Tuazon CU, Wells MA, Butchko GM, Armstrong R, McLaren C, Manischewitz JF, Kiley S. Cytotoxic lymphocytes and antibody-dependent complement-mediated cytotoxicity induced by administration of influenza vaccine. Infect Immun 1980; 30:362-9; PMID:7439982
24. Verbonitz MW, Ennis FA, Hicks JT, Albrecht P. Hemagglutinin-specific complement-dependent cytolytic antibody response to influenza infection. J Exp Med 1978; 147:265-70; PMID:627837; https://doi.org/10.1084/jem.147.1.265
25. Mullarkey CE, Bailey MJ, Golubeva DA, Tan GS, Nachbagauer R, He W, Novakowski KE, Bowdish DM, Miller MS, Palese P. Broadly Neutralizing Hemagglutinin Stalk-Specific Antibodies Induce Potent Phagocytosis of Immune Complexes by Neutrophils in an Fc-Dependent Manner. mBio 2016; 7:e01624-16; PMID:27703076; https://doi.org/10.1128/mBio.01624-16
26. Ana-Sosa-Batiz F, Vanderven H, Jegaskanda S, Johnston A, Rockman S, Laurie K, Barr I, Reading P, Lichtfuss M, Kent SJ. Influenza-Specific Antibody-Dependent Phagocytosis. PLoS One 2016; 11:e0154461; PMID:27124730; https://doi.org/10.1371/journal.pone.0154461
27. DiLillo DJ, Tan GS, Palese P, Ravetch JV. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo. Nat Med 2014; 20:143-51; PMID:24412922; https://doi.org/10.1038/nm.3443
28. Jegaskanda S, Reading PC, Kent SJ. Influenza-specific antibody-dependent cellular cytotoxicity:toward a universal influenza vaccine. J Immunol 2014; 193:469-75; PMID:24994909; https://doi.org/10.4049/jimmunol.1400432
29. Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, Jarrossay D, Vachieri SG, Pinna D, Minola A, Vanzetta F, et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 2011; 333:850-6; PMID:21798894; https://doi.org/10.1126/science.1205669
30. Fu Y, Zhang Z, Sheehan J, Avnir Y, Ridenour C, Sachnik T, Sun J, Hossain MJ, Chen LM, Zhu Q, et al. A broadly neutralizing anti-influenza antibody reveals ongoing capacity of haemagglutinin-specific memory B cells to evolve. Nat Commun 2016; 7:12780; PMID:27619409; https://doi.org/10.1038/ncomms12780
31. Bournazos S, DiLillo DJ, Ravetch JV. The role of Fc-FcgammaR interactions in IgG-mediated microbial neutralization. J Exp Med 2015; 212:1361-9; PMID:26282878; https://doi.org/10.1084/jem.20151267
32. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol 2001; 19:275-90; PMID:11244038; https://doi.org/10.1146/annurev.immunol.19.1.275
33. Greenberg SB, Criswell BS, Six HR, Couch RB. Lymphocyte cytotoxicity to influenza virus-infected cells:response to vaccination and virus infection. Infect Immun 1978; 20:640-5; PMID:669816
34. Greenberg SB, Criswell BS, Six HR, Couch RB. Lymphocyte cytotoxicity to influenza virus-infected cells. II. Requirement for antibody and non-T lymphocytes. J Immunol 1977; 119:2100-6
35. Hashimoto G, Wright PF, Karzon DT. Antibody-dependent cell-mediated cytotoxicity against influenza virus-infected cells. J Infect Dis 1983; 148:785-94; PMID:6605395; https://doi.org/10.1093/infdis/148.5.785
36. Jegaskanda S, Luke C, Hickman HD, Sangster MY, Wieland-Alter WF, McBride JM, Yewdell JW, Wright PF, Treanor J, Rosenberger CM, et al. Generation and protective ability of influenza virus-specific antibody-dependent cellular cytotoxicity in humans elicited by vaccination, natural infection, and experimental challenge. J Infect Dis 2016; 214:945-52; PMID:27354365; https://doi.org/10.1093/infdis/jiw262
37. Wright PF, Hoen AG, Ilyushina NA, Brown EP, Ackerman ME, Wieland-Alter W, Connor RI, Jegaskanda S, Rosenberg-Hasson Y, Haynes BC, et al. Correlates of immunity to influenza as determined by challenge of children with live, attenuated influenza vaccine. Open Forum Infect Dis 2016; 3:ofw108; PMID:27419180; https://doi.org/10.1093/ofid/ofw108
38. Hashimoto G, Wright PF, Karzon DT. Ability of human cord blood lymphocytes to mediate antibody-dependent cellular cytotoxicity against influenza virus-infected cells. Infect Immun 1983; 42:214-8; PMID:6604697
39. Co MD, Terajima M, Thomas SJ, Jarman RG, Rungrojcharoenkit K, Fernandez S, Yoon IK, Buddhari D, Cruz J, Ennis FA. Relationship of preexisting influenza hemagglutination inhibition, complement-dependent lytic, and antibody-dependent cellular cytotoxicity antibodies to the development of clinical illness in a prospective study of A(H1N1)pdm09 Influenza in children. Viral Immunol 2014; 27:375-82; PMID:25141276; https://doi.org/10.1089/vim.2014.0061
40. Jegaskanda S, Co MD, Cruz J, Subbarao K, Ennis FA, Terajima M. Human seasonal influenza A viruses induce H7N9-cross-reactive antibody-dependent cellular cytotoxicity (ADCC) antibodies that are directed towards the nucleoprotein. J Infect Dis 2016; https://doi.org/10.1093/infdis/jiw629
41. Jegaskanda S, Laurie KL, Amarasena TH, Winnall WR, Kramski M, De Rose R, Barr IG, Brooks AG, Reading PC, Kent SJ. Age-associated cross-reactive antibody-dependent cellular cytotoxicity toward 2009 pandemic influenza A virus subtype H1N1. J Infect Dis 2013; 208:1051-61; PMID:23812238; https://doi.org/10.1093/infdis/jit294
42. Mesman AW, Westerhuis BM, Ten Hulscher HI, Jacobi RH, de Bruin E, van Beek J, Buisman AM, Koopmans MP, van Binnendijk RS. Influenza virus A(H1N1)2009 antibody-dependent cellular cytotoxicity in young children prior to the H1N1 pandemic. J Gen Virol 2016; 97:2157-65; PMID:27412007; https://doi.org/10.1099/jgv.0.000552
43. de Vries RD, Nieuwkoop NJ, Pronk M, de Bruin E, Leroux-Roels G, Huijskens EG, van Binnendijk RS, Krammer F, Koopmans MP, Rimmelzwaan GF. Influenza virus-specific antibody dependent cellular cytoxicity induced by vaccination or natural infection. Vaccine 2017; 35:238-47; PMID:27914742; https://doi.org/10.1016/j.vaccine.2016.11.082
44. Jegaskanda S, Weinfurter JT, Friedrich TC, Kent SJ. Antibody-dependent cellular cytotoxicity is associated with control of pandemic H1N1 influenza virus infection of macaques. J Virol 2013; 87:5512-22; PMID:23468501; https://doi.org/10.1128/JVI.03030-12
45. Jegaskanda S, Amarasena TH, Laurie KL, Tan HX, Butler J, Parsons MS, Alcantara S, Petravic J, Davenport MP, Hurt AC, et al. Standard trivalent influenza virus protein vaccination does not prime antibody-dependent cellular cytotoxicity in macaques. J Virol 2013; 87:13706-18; PMID:24109221; https://doi.org/10.1128/JVI.01666-13
46. Koopman G, Mooij P, Dekking L, Mortier D, Nieuwenhuis IG, van Heteren M, Kuipers H, Remarque EJ, Radošević K, Bogers WM. Correlation between Virus Replication and Antibody Responses in Macaques following Infection with Pandemic Influenza A Virus. J Virol 2015; 90:1023-33; PMID:26537681; https://doi.org/10.1128/JVI.02757-15
47. Vanderven HA, Ana-Sosa-Batiz F, Jegaskanda S, Rockman S, Laurie K, Barr I, Chen W, Wines B, Hogarth PM, Lambe T, et al. What Lies Beneath:Antibody Dependent Natural Killer Cell Activation by Antibodies to Internal Influenza Virus Proteins. EBioMedicine 2016; 8:277-90; PMID:27428437; https://doi.org/10.1016/j.ebiom.2016.04.029
48. Kristensen AB, Lay WN, Ana-Sosa-Batiz F, Vanderven HA, Madhavi V, Laurie KL, Carolan L, Wines BD, Hogarth M, Wheatley AK, et al. Antibody Responses with Fc-Mediated Functions after Vaccination of HIV-Infected Subjects with Trivalent Influenza Vaccine. J Virol 2016; 90:5724-34; PMID:27053553; https://doi.org/10.1128/JVI.00285-16
49. Zhong W, Gross FL, Holiday C, Jefferson SN, Bai Y, Liu F, Katz JM, Levine MZ. Vaccination with 2014-15 Seasonal Inactivated Influenza Vaccine Elicits Cross-Reactive Anti-HA Antibodies with Strong ADCC Against Antigenically Drifted Circulating H3N2 Virus in Humans. Viral Immunol 2016; 29:259-62; PMID:26950058; https://doi.org/10.1089/vim.2016.0003
50. Zhong W, Liu F, Wilson JR, Holiday C, Li ZN, Bai Y, Tzeng WP, Stevens J, York IA, Levine MZ. Antibody-Dependent Cell-Mediated Cytotoxicity to Hemagglutinin of Influenza A Viruses After Influenza Vaccination in Humans. Open Forum Infect Dis 2016; 3:ofw102; PMID:27419174; https://doi.org/10.1093/ofid/ofw102
51. Sobhanie M, Matsuoka Y, Jegaskanda S, Fitzgerald T, Mallory R, Chen Z, Luke C, Treanor J, Subbarao K. Evaluation of the Safety and Immunogenicity of a Candidate Pandemic Live Attenuated Influenza Vaccine (pLAIV) Against Influenza A(H7N9). J Infect Dis 2016; 213:922-9; PMID:26655841; https://doi.org/10.1093/infdis/jiv526
52. Florek NW, Weinfurter JT, Jegaskanda S, Brewoo JN, Powell TD, Young GR, Das SC, Hatta M, Broman KW, Hungnes O, et al. Modified vaccinia virus Ankara encoding influenza virus hemagglutinin induces heterosubtypic immunity in macaques. J Virol 2014; 88:13418-28; PMID:25210172; https://doi.org/10.1128/JVI.01219-14
53. Goodier MR, Lusa C, Sherratt S, Rodriguez-Galan A, Behrens R, Riley EM. Sustained Immune Complex-Mediated Reduction in CD16 Expression after Vaccination Regulates NK Cell Function. Front Immunol 2016; 7:384; PMID:27725819; https://doi.org/10.3389/fimmu.2016.00384
54. DiLillo DJ, Palese P, Wilson PC, Ravetch JV. Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection. J Clin Invest 2016; 126:605-10; PMID:26731473; https://doi.org/10.1172/JCI84428
55. He W, Tan GS, Mullarkey CE, Lee AJ, Lam MM, Krammer F, Henry C, Wilson PC, Ashkar AA, Palese P, et al. Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus. Proc Natl Acad Sci U S A 2016; 113:11931-6; PMID:27698132; https://doi.org/10.1073/pnas.1609316113
56. Leon PE, He W, Mullarkey CE, Bailey MJ, Miller MS, Krammer F, Palese P, Tan GS. Optimal activation of Fc-mediated effector functions by influenza virus hemagglutinin antibodies requires two points of contact. Proc Natl Acad Sci U S A 2016; 113:E5944-E51; PMID:27647907; https://doi.org/10.1073/pnas.1613225113
57. Cox F, Kwaks T, Brandenburg B, Koldijk MH, Klaren V, Smal B, Korse HJ, Geelen E, Tettero L, Zuijdgeest D, et al. HA Antibody-Mediated FcgammaRIIIa Activity Is Both Dependent on FcR Engagement and Interactions between HA and Sialic Acids. Front Immunol 2016; 7:399; PMID:27746785; https://doi.org/10.3389/fimmu.2016.00399
58. Jegaskanda S, Vandenberg K, Laurie KL, Loh L, Kramski M, Winnall WR, Kedzierska K, Rockman S, Kent SJ. Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity in intravenous immunoglobulin as a potential therapeutic against emerging influenza viruses. J Infect Dis 2014; 210:1811-22; PMID:24916185; https://doi.org/10.1093/infdis/jiu334
59. Bodewes R, Geelhoed-Mieras MM, Wrammert J, Ahmed R, Wilson PC, Fouchier RA, Osterhaus AD, Rimmelzwaan GF. In vitro assessment of the immunological significance of a human monoclonal antibody directed to the influenza a virus nucleoprotein. Clin Vaccine Immunol 2013; 20:1333-7; PMID:23761662; https://doi.org/10.1128/CVI.00339-13
60. Yewdell JW, Frank E, Gerhard W. Expression of influenza A virus internal antigens on the surface of infected P815 cells. J Immunol 1981; 126:1814-9
61. Carragher DM, Kaminski DA, Moquin A, Hartson L, Randall TD. A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus. J Immunol 2008; 181:4168-76; https://doi.org/10.4049/jimmunol.181.6.4168
62. LaMere MW, Lam HT, Moquin A, Haynes L, Lund FE, Randall TD, Kaminski DA. Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus. J Immunol 2011; 186:4331-9; https://doi.org/10.4049/jimmunol.1003057
63. Lamb RA, Zebedee SL, Richardson CD. Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface. Cell 1985; 40:627-33; PMID:3882238; https://doi.org/10.1016/0092-8674(85)90211-9
64. El Bakkouri K, Descamps F, De Filette M, Smet A, Festjens E, Birkett A, Van Rooijen N, Verbeek S, Fiers W, Saelens X. Universal vaccine based on ectodomain of matrix protein 2 of influenza A:Fc receptors and alveolar macrophages mediate protection. J Immunol 2011; 186:1022-31; https://doi.org/10.4049/jimmunol.0902147
65. Wang R, Song A, Levin J, Dennis D, Zhang NJ, Yoshida H, Koriazova L, Madura L, Shapiro L, Matsumoto A, et al. Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein. Antiviral Res 2008; 80:168-77; PMID:18598723; https://doi.org/10.1016/j.antiviral.2008.06.002
66. Simhadri VR, Dimitrova M, Mariano JL, Zenarruzabeitia O, Zhong W, Ozawa T, Muraguchi A, Kishi H, Eichelberger MC, Borrego F. A Human Anti-M2 Antibody Mediates Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Cytokine Secretion by Resting and Cytokine-Preactivated Natural Killer (NK) Cells. PLoS One 2015; 10:e0124677; PMID:25915748; https://doi.org/10.1371/journal.pone.0124677
67. Jegerlehner A, Schmitz N, Storni T, Bachmann MF. Influenza A vaccine based on the extracellular domain of M2:weak protection mediated via antibody-dependent NK cell activity. J Immunol 2004; 172:5598-605; https://doi.org/10.4049/jimmunol.172.9.5598
68. Kim MC, Lee YN, Hwang HS, Lee YT, Ko EJ, Jung YJ, Cho MK, Kim YJ, Lee JS, Ha SH, et al. Influenza M2 virus-like particles confer a broader range of cross protection to the strain-specific pre-existing immunity. Vaccine 2014; 32:5824-31; PMID:25171841; https://doi.org/10.1016/j.vaccine.2014.08.030
69. Lee YN, Kim MC, Lee YT, Hwang HS, Lee J, Kim C, Kang SM. Cross Protection against Influenza A Virus by Yeast-Expressed Heterologous Tandem Repeat M2 Extracellular Proteins. PLoS One 2015; 10:e0137822; PMID:26366729; https://doi.org/10.1371/journal.pone.0137822
70. Lee YN, Lee YT, Kim MC, Hwang HS, Lee JS, Kim KH, Kang SM. Fc receptor is not required for inducing antibodies but plays a critical role in conferring protection after influenza M2 vaccination. Immunology 2014; 143:300-9; PMID:24773389; https://doi.org/10.1111/imm.12310
71. Song JM, Wang BZ, Park KM, Van Rooijen N, Quan FS, Kim MC, Jin HT, Pekosz A, Compans RW, Kang SM. Influenza virus-like particles containing M2 induce broadly cross protective immunity. PLoS One 2011; 6:e14538; PMID:21267073; https://doi.org/10.1371/journal.pone.0014538
72. Bruhns P. Properties of mouse and human IgG receptors and their contribution to disease models. Blood 2012; 119:5640-9; PMID:22535666; https://doi.org/10.1182/blood-2012-01-380121
73. Bruhns P, Jonsson F. Mouse and human FcR effector functions. Immunol Rev 2015; 268:25-51; PMID:26497511; https://doi.org/10.1111/imr.12350
74. Jegaskanda S, Job ER, Kramski M, Laurie K, Isitman G, de Rose R, Winnall WR, Stratov I, Brooks AG, Reading PC, et al. Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies. J Immunol 2013; 190:1837-48; https://doi.org/10.4049/jimmunol.1201574
75. Wines BD, Vanderven HA, Esparon SE, Kristensen AB, Kent SJ, Hogarth PM. Dimeric FcgammaR Ectodomains as Probes of the Fc Receptor Function of Anti-Influenza Virus IgG. J Immunol 2016; 197:1507-16; https://doi.org/10.4049/jimmunol.1502551
76. Smalls-Mantey A, Doria-Rose N, Klein R, Patamawenu A, Migueles SA, Ko SY, Hallahan CW, Wong H, Liu B, You L, et al. Antibody-dependent cellular cytotoxicity against primary HIV-infected CD4+ T cells is directly associated with the magnitude of surface IgG binding. J Virol 2012; 86:8672-80; PMID:22674985; https://doi.org/10.1128/JVI.00287-12
77. Smyth MJ, Cretney E, Kelly JM, Westwood JA, Street SE, Yagita H, Takeda K, van Dommelen SL, Degli-Esposti MA, Hayakawa Y. Activation of NK cell cytotoxicity. Mol Immunol 2005; 42:501-10; PMID:15607806; https://doi.org/10.1016/j.molimm.2004.07.034
78. Mocsai A. Diverse novel functions of neutrophils in immunity, inflammation, and beyond. J Exp Med 2013; 210:1283-99; PMID:23825232; https://doi.org/10.1084/jem.20122220
79. Smalls-Mantey A, Connors M, Sattentau QJ. Comparative efficiency of HIV-1-infected T cell killing by NK cells, monocytes and neutrophils. PLoS One 2013; 8:e74858; PMID:24040353; https://doi.org/10.1371/journal.pone.0074858
80. Horner H, Frank C, Dechant C, Repp R, Glennie M, Herrmann M, Stockmeyer B. Intimate cell conjugate formation and exchange of membrane lipids precede apoptosis induction in target cells during antibody-dependent, granulocyte-mediated cytotoxicity. J Immunol 2007; 179:337-45; https://doi.org/10.4049/jimmunol.179.1.337
81. Koller CA, LoBuglio AF. Monocyte-mediated antibody-dependent cell-mediated cytotoxicity:the role of the metabolic burst. Blood 1981; 58:293-9; PMID:6264996
82. Saitoh T, Komano J, Saitoh Y, Misawa T, Takahama M, Kozaki T, Uehata T, Iwasaki H, Omori H, Yamaoka S, et al. Neutrophil extracellular traps mediate a host defense response to human immunodeficiency virus-1. Cell Host Microbe 2012; 12:109-16; https://doi.org/10.1016/j.chom.2012.05.015
83. Metkar SS, Froelich CJ. Human neutrophils lack granzyme A, granzyme B, and perforin. Blood 2004; 104:905-6; author reply 7-8; PMID:15265799; https://doi.org/10.1182/blood-2004-03-0888
84. Metelitsa LS, Gillies SD, Super M, Shimada H, Reynolds CP, Seeger RC. Antidisialoganglioside/granulocyte macrophage-colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on FcgammaRII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and azurophil granule exocytosis. Blood 2002; 99:4166-73; PMID:12010822; https://doi.org/10.1182/blood.V99.11.4166
85. Henry Dunand CJ, Leon PE, Huang M, Choi A, Chromikova V, Ho IY, Tan GS, Cruz J, Hirsh A, Zheng NY, et al. Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer Protection. Cell Host Microbe 2016; 19:800-13; https://doi.org/10.1016/j.chom.2016.05.014
86. Yeap WH, Wong KL, Shimasaki N, Teo EC, Quek JK, Yong HX, Diong CP, Bertoletti A, Linn YC, Wong SC. CD16 is indispensable for antibody-dependent cellular cytotoxicity by human monocytes. Sci Rep 2016; 6:34310; PMID:27670158; https://doi.org/10.1038/srep34310
87. lavazhagan S, Fatehchand K, Santhanam V, Fang H, Ren L, Gautam S, Reader B, Mo X, Cheney C, Briercheck E, et al. Granzyme B expression is enhanced in human monocytes by TLR8 agonists and contributes to antibody-dependent cellular cytotoxicity. J Immunol 2015; 194:2786-95; https://doi.org/10.4049/jimmunol.1402316
88. Ferrari G, Pollara J, Kozink D, Harms T, Drinker M, Freel S, Moody MA, Alam SM, Tomaras GD, Ochsenbauer C, et al. An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum. J Virol 2011; 85:7029-36; PMID:21543485; https://doi.org/10.1128/JVI.00171-11